Novo Nordisk A/S

5 hours ago · zacks.com

NVO faces intensifying GLP-1 competition, earnings cuts and pricing pressure, challenging its growth outlook ahead of Q3 results.

3 days ago · zacks.com

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

3 days ago · fool.com

Novo plans to expand its lineup and pipeline by 2030, while serving far more patients. The company seems well positioned to accomplish many of its goals.

5 days ago · zacks.com

In the latest trading session, Novo Nordisk (NVO) closed at $38.7, marking a -1.11% move from the previous day.

5 days ago · seekingalpha.com

Eli Lilly and Company has decisively outpaced Novo Nordisk A/S in the GLP-1/obesity/T2D market, now commanding a $1.21T valuation. NVO's share price has retraced all post-Wegovy gains; revenue growth is stagnant, but management's reset and pipeline strategy prompt a Buy upgrade. LLY's pipeline, momentum, and manufacturing strength support continued dominance, with the potential to surpass $100B in annual revenues as early as next year.

7 days ago · globenewswire.com

DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews. com) - Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), AstraZeneca (NYSE: AZN), and Roche (OTCQX: RHHBY) are among the biopharma companies committing billions of dollars to new manufacturing facilities as obesity medicines become a major commercial opportunity.

8 days ago · seekingalpha.com

Our top performer in the third quarter was TVA Group, which gained 46.7%. TVA's first-half earnings reached levels not seen in over a decade. Intercontinental Exchange advanced 23.5% in Q3, validating our view in Scorecard 54 that the regulatory panic surrounding perpetual futures was overdone. Portfolio stalwart Visa Inc. was our third-best contributor in Q3, advancing 4.7% as payment volumes and revenues sustained their double-digit growth.

11 days ago · zacks.com

Viking Therapeutics' late-stage obesity drug and promising weight-maintenance data could offer greater upside than Novo Nordisk, despite higher clinical and commercial risks.

12 days ago · fool.com

Novo remains a leader in the diabetes and weight loss drug markets. The company could make significant clinical and regulatory progress over the next few years.

13 days ago · invezz.com

Novo Nordisk shares NVO rose on Tuesday after the Danish drugmaker reported that its experimental weight-loss drug CagriSema helped women with obesity or overweight lose an average of 25% of their body weight in a late-stage clinical study. The stock gained more than 2% as investors assessed the findings for a potential successor to Wegovy, Novo's blockbuster obesity treatment.